These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Prostaglandins E1 in the treatment of neonatal cardiopathies related to ductus arteriosus. 19 cases]. Maesen Y, Bosi G, Stijns M, Vliers A. Arch Mal Coeur Vaiss; 1981 May; 74(5):579-85. PubMed ID: 6794479 [Abstract] [Full Text] [Related]
5. Prostaglandin E2 administration in infants with ductus-dependent cyanotic congenital heart disease. Thanopoulos BD, Andreou A, Frimas C. Eur J Pediatr; 1987 May; 146(3):279-82. PubMed ID: 3474149 [Abstract] [Full Text] [Related]
9. Evaluation of alprostadil (prostaglandin E1) in the management of congenital heart disease in infancy. Heymann MA, Clyman RI. Pharmacotherapy; 1982 Apr; 2(3):148-55. PubMed ID: 6763200 [Abstract] [Full Text] [Related]
10. Use of prostaglandin E2 in management of transposition of great arteries before balloon atrial septostomy. Beitzke A, Suppan CH. Br Heart J; 1983 Apr; 49(4):341-4. PubMed ID: 6572529 [Abstract] [Full Text] [Related]
12. [Use of prostaglandin E1 in ductus-dependent congenital cardiopathies]. Marcial MB, Maluf M, Atik E, Vargas H, Baucia JA, Verginelli G. Arq Bras Cardiol; 1983 Jun; 40(6):383-6. PubMed ID: 6686760 [No Abstract] [Full Text] [Related]
13. Pharmacologic dilatation of the ductus arteriosus with prostaglandin E1 in infants with congenital heart disease. Graham TP, Atwood GF, Boucek RJ. South Med J; 1978 Oct; 71(10):1238-41, 1246. PubMed ID: 81528 [Abstract] [Full Text] [Related]
14. Effects of prostaglandin E1 infusion in the pre-operative management of critical congenital heart disease. Ohara T, Ogata H, Fujiyama J, Murata Y, Abe J, Kakuta K, Hayamizu S, Kameyama S, Yoshida Y. Tohoku J Exp Med; 1985 Jun; 146(2):237-49. PubMed ID: 4040664 [Abstract] [Full Text] [Related]
15. Prolonged prostaglandin E1 infusion in an infant with cyanotic congenital heart disease. Lewis AB, Lurie PR. Pediatrics; 1978 Apr; 61(4):534-6. PubMed ID: 662477 [Abstract] [Full Text] [Related]
16. Pharmacologic use of prostaglandin E1 in infant with congenital heart disease. Heymann MA. Am Heart J; 1981 Jun; 101(6):837-43. PubMed ID: 7234660 [No Abstract] [Full Text] [Related]
17. Neurological and electroencephalographic changes in newborns treated with prostaglandins E1 and E2. Fariello R, Olley PM, Coceani F. Prostaglandins; 1977 May; 13(5):901-7. PubMed ID: 866697 [Abstract] [Full Text] [Related]
18. Use of prostaglandin E1 in infants with d-transposition of the great arteries and intact ventricular septum. Lang P, Freed MD, Bierman FZ, Norwood WI, Nadas AS. Am J Cardiol; 1979 Jul; 44(1):76-81. PubMed ID: 88172 [Abstract] [Full Text] [Related]
19. Prostaglandin E1 in infants with pulmonary atresia. Weir EK, Matisonn RE, Losman E, Chesler E. S Afr Med J; 1978 Oct 21; 54(17):700-2. PubMed ID: 741285 [Abstract] [Full Text] [Related]
20. Palliation of cyanotic congenital heart disease in infancy with E-type prostaglandins. Neutze JM, Starling MB, Elliott RB, Barratt-Boyes BG. Circulation; 1977 Feb 21; 55(2):238-41. PubMed ID: 64317 [Abstract] [Full Text] [Related] Page: [Next] [New Search]